Related Experiment Videos

Possible association of ACE gene I/D polymorphism with blood pressure--lowering response to hydrochlorothiazide

Yong Zhou1, Shou-Ling Wu, Jian-Qing Liu

  • 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China. yongzhou78214@163.com

Biomedical and Environmental Sciences : BES
|January 15, 2008
PubMed

Insights

The angiotensin-converting enzyme (ACE) I/D gene polymorphism influences hydrochlorothiazide (HCTZ) effectiveness. Patients with the DD genotype show a greater blood pressure reduction with HCTZ treatment.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Genetics

Background:

  • Hydrochlorothiazide (HCTZ) is a widely used diuretic for hypertension management.
  • Individual variability in drug response necessitates personalized treatment approaches.
  • The angiotensin-converting enzyme (ACE) I/D gene polymorphism is a potential factor influencing cardiovascular drug efficacy.

Purpose of the Study:

  • To investigate the association between ACE I/D gene polymorphism and the blood pressure-lowering response to HCTZ.
  • To determine if specific ACE genotypes predict treatment outcomes in hypertensive patients receiving HCTZ.

Main Methods:

  • A cohort of 829 patients was analyzed.
  • Patients received a daily dose of 12.5 mg HCTZ for six weeks.
  • Blood pressure reduction and achievement of target blood pressure were compared across different ACE genotype groups (II, ID, DD).

Main Results:

  • Patients with the DD genotype exhibited significantly greater reductions in systolic blood pressure (SBP) and mean arterial pressure (MAP) compared to II or ID genotypes.
  • The proportion of patients reaching target blood pressure was significantly higher in the DD genotype group.
  • Pre-treatment SBP, MAP, aldosterone levels, and the DD genotype were identified as significant predictors in multi-linear regression models for SBP and MAP reduction.

Conclusions:

  • ACE genotyping is significantly associated with the blood pressure-lowering response to HCTZ.
  • Specific ACE genotypes may predict the efficacy of HCTZ as an antihypertensive treatment, supporting a personalized medicine approach.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...